Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Drug Eruptions
  Follow Topic   Edit Search
Your search returned 30 results
from the time period: last 6 months.
Sort by Relevance / Date Group By Journal / No Grouping
The Lancet. Oncology 
DescriptorName: Drug Eruptions... Safety was analysed in all patients who received at least one dose of study drug and had at least one post-baseline safety assessment according to the treatment they received. This trial is registered with ClinicalTrials.gov, number NCT01610284, and is currently ongoing but not recruiting participants AbstractText: Between Sept 7, 2012, and Sept 10, 2014, 1147 ...
Oncology (8)
Breast Neoplasms (6), Neoplasms (4), Exanthema (1), more mentions
The Lancet. Oncology 
BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would improve toxicity, quality of life, or both. METHODS: In this multicentre, phase 3, randomised, controlled trial, we enrolled patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy. Patients were randomly assigned to receive four cycles of 100 mg/m(2) epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m(2) cyclophosphamide intravenously on days 1 and 8 or 100 mg/m(2) orally on days 1-14; 40 mg/m(2) methotrexate intravenously on days 1 and 8; and 600 mg/m(2) fluorouracil intravenously on days 1 and 8 of each cycle) or four 3-week cycles of 2500 mg/m(2) capecitabine (1250 mg/m(2) given twice daily on days 1-14 of each cycle). The randomisation schedule was computer generated in random permuted blocks, stratified by centre, number of nodes involved (none vs one to three vs four or more), age (≤50 years vs >50 years), and planned endocrine treatment (yes vs no). The primary endpoint was TTR, defined as time from randomisation to first invasive relapse or breast cancer death, with intention-to-treat analysis of standard versus accelerated epirubicin and per-protocol analysis of CMF versus capecitabine. This trial is registered with ISRCTN, number 68068041, and with ClinicalTrials.gov, number NCT00301925. FINDINGS: From Dec 16, 2005, to Dec 5, 2008, 4391 patients (4371 women and 20 men) were recruited. At a median follow-up of 85·6 months (IQR 80·6-95·9) no significant difference was seen in the proportions of patients free from TTR events between the accelerated and standard epirubicin groups (overall hazard ratio [HR] 0·94, 95% CI 0·81-1·09; stratified p=0·42). At 5 years, 85·9% (95% CI 84·3-87·3) of patients receiving standard epirubicin and 87·1% (85·6-88·4) of those receiving accelerated epirubicin were free from TTR events. 4358 patients were included in the per-protocol analysis, and no difference was seen in the proportions of patients free from TTR events between the CMF and capecitabine groups (HR 0·98, 95% CI 0·85-1.14; stratified p=0·00092 for non-inferiority). Compared with baseline, significantly more patients taking CMF than those taking capecitabine had clinically relevant worsening of quality of life at end of treatment (255 [58%] of 441 vs 235 [50%] of 475; p=0·011) and at 12 months (114 [34%] of 334 vs 89 [22%] of 401; p<0·001 at 12 months) and had worse quality of life over time (p<0·0001). Detailed toxicity and quality-of-life data were collected from 2115 (48%) of treated patients. The most common grade 3 or higher adverse events in cycles 1-4 were neutropenia (175 [16%]) and fatigue (56 [5%]) of the 1070 patients treated with standard epirubicin, and fatigue (63 [6%]) and infection (34 [3%]) of the 1045 patients treated with accelerated epirubicin. In cycles 5-8, the most common grade 3 or higher adverse events were neutropenia (321 [31%]) and fatigue (109 [11%]) in the patients treated with CMF, and hand-foot syndrome (129 [12%]) and diarrhoea (67 [6%]) in the 1044 patients treated with capcitabine. INTERPRETATION: We found no benefit from increasing the dose density of the anthracycline component of chemotherapy. However, capecitabine could be used in place of CMF without significant loss of efficacy and with improved quality of life. FUNDING: Cancer Research UK, Amgen, Pfizer, and Roche.
Oncology (6)
Breast Neoplasms (6), Neutropenia (3), Infections (2), more mentions
The New England journal of medicine 
BACKGROUND: Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. METHODS: We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either with capecitabine or without (control). The primary end point was disease-free survival. Secondary end points included overall survival. RESULTS: The result of the prespecified interim analysis met the primary end point, so this trial was terminated early. The final analysis showed that disease-free survival was longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years; hazard ratio for recurrence, second cancer, or death, 0.70; 95% confidence interval [CI], 0.53 to 0.92; P=0.01). Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P=0.01). Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90). The hand-foot syndrome, the most common adverse reaction to capecitabine, occurred in 73.4% of the patients in the capecitabine group. CONCLUSIONS: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. (Funded by the Advanced Clinical Research Organization and the Japan Breast Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, UMIN000000843 .).
Oncology (9)
Breast Neoplasms (7), Second Primary Neoplasms (3), Hand-Foot Syndrome (2), more mentions
The Lancet. Oncology 
AbstractText: The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic ... Approval of this drug was based on progression-free survival and interim overall survival data from the phase ... capecitabine and 241 [49%] of 495 received lapatinib (separately or in combination) after study drug discontinuation.
Oncology (4), Blood Disorders and Hematology (1)
Breast Neoplasms (6), Thrombocytopenia (2), Coronary Artery Disease (1), more mentions
JAMA dermatology
... histopathologic presentations have varied considerably AbstractText: To characterize purpuric skin eruptions caused by epidermal growth factor receptor inhibitors AbstractText: This prospective ... features, laboratory examinations, and treatment outcomes of patients with purpuric drug eruptions AbstractText: Thirty-two patients, 14 with purpuric drug eruptions without pustules (mean [SD] age, 60 [11] years; 12 female and 2 male) and 18 with purpuric drug eruptions with pustules (mean [SD] age, 64 [11] years; 12 ...
Infectious Diseases (1), Oncology (1)
Drug Eruptions (6), Lung Neoplasms (2), Carcinoma (1), more mentions
The British journal of surgery 
CitationSubset: AIM. CitationSubset: IM. DescriptorName: Anti-Bacterial Agents. DescriptorName: Anti-Infective Agents, Local. DescriptorName: Drug Eruptions. DescriptorName: Humans. DescriptorName: Randomized Controlled Trials as Topic. DescriptorName: Surgical Wound Infection. DescriptorName: Wound Closure Techniques. DescriptorName: Wound Healing. AbstractText: Surgical-site infections (SSIs) increase patient morbidity and costs. The aim was to identify and synthesize all RCTs evaluating the effect of topical antibiotics ...
Infectious Diseases (10), Dermatology (3)
Allergic Contact Dermatitis (3), Infections (2), Surgical Wound Infections (1), more mentions
The Journal of family practice
CitationSubset: AIM. CitationSubset: IM. DescriptorName: Adult. DescriptorName: Drug Hypersensitivity Syndrome. DescriptorName: Exanthema. DescriptorName: Fever. DescriptorName: Humans. DescriptorName: Leukopenia. DescriptorName: Male. Abstract: A 32-year-old man was admitted to our hospital with fever, chills, malaise, leukopenia, and a rash. About 3 weeks earlier, he'd had oral maxillofacial surgery and started a 10-day course of prophylactic amoxicillin/clavulanic acid.
Infectious Diseases (2)
Leukopenia (4), Arthralgia (1), Exanthema (1), more mentions
The Journal of investigative dermatology
Sixty years after its original description by Sir Alan Lyell, epidermal necrolysis (from Stevens-Johnson syndrome to toxic epidermal necrolysis) seems finally amenable to a specific treatment in addition to essential symptomatic measures in specialized settings. A recently published systematic review and an article by Gonzales-Herrada et al. strongly suggest that cyclosporine is effective in reducing the risk of death.
Stevens-Johnson Syndrome (2), Toxic Epidermal Necrolysis (1), more mentions
The Journal of investigative dermatology
Several immunomodulatory agents are used in the treatment of epidermal necrolysis, but evidence of their efficacy is limited. The Autonomous Community of Madrid has two reference burn units to which all patients with epidermal necrolysis are referred. One burn unit has mostly used cyclosporine (CsA), and the other has used non-CsA therapies (mainly high-dose intravenous immunoglobulin). The allocation of patients to one or the other burn unit was mainly based on proximity, resembling a random assignment. Thus, we took advantage of this "natural experiment" to estimate the mortality risk ratio (MRR) of CsA (n = 26) compared with non-CsA (n = 16) treatment using hospital as an instrumental variable over the period from 2001 to 2015. We also computed the observed versus expected (O/E) MRR in a case series of 49 CsA-treated patients (including 23 patients from other regions treated in Madrid), and using the Score for Toxic Epidermal Necrolysis (i.e., SCORTEN) scale to estimate the expected values. The instrumental variable-based MRR of CsA versus non-CsA was 0.09 (95% confidence interval = 0.00-0.49). The O/E analysis also showed a reduction in mortality risk (MRROE = 0.42; 95% confidence interval = 0.14-0.99). We identified five other case series of CsA-treated patients providing MRROE and meta-analyzed their results. The pooled MRROE (including from this study) was 0.41 (95% confidence interval = 0.21-0.80). All three approaches consistently show that CsA reduces the mortality in epidermal necrolysis patients.
Toxic Epidermal Necrolysis (1), Stevens-Johnson Syndrome (1), more mentions
The American journal of surgical pathology
DescriptorName: Drug Eruptions... Abstract: Cutaneous eruptions are among the most common immune-related adverse events (irAEs ... Sixteen patients with 17 biopsied eruptions were included from 2 academic institutions with extensive experience administering ... Eruptions occurred a median of 10 days (range, 1 d to ... and 19% of patients discontinued immunotherapy due to their skin eruptions.
Dermatology (1)
Neoplasms (2), Bullous Pemphigoid (1), Exanthema (1), more mentions
British journal of cancer
DescriptorName: Antibodies, Monoclonal, Humanized. DescriptorName: Antineoplastic Combined Chemotherapy Protocols. DescriptorName: Breast Neoplasms. DescriptorName: Camptothecin. DescriptorName: Carcinoma, Non-Small-Cell Lung. DescriptorName: Deoxycytidine. DescriptorName: Diarrhea. DescriptorName: Doxorubicin. DescriptorName: Drug Eruptions. DescriptorName: Fatigue. DescriptorName: Female. DescriptorName: Humans. DescriptorName: Lung Neoplasms. DescriptorName: Male. DescriptorName: Middle Aged. DescriptorName: Nausea. DescriptorName: Neoplasms. DescriptorName: Ovarian Neoplasms.
Oncology (1)
Carcinoma (2), Neoplasms (2), Pancreatic Neoplasms (1), more mentions
British journal of cancer
DescriptorName: Adult. DescriptorName: Aged. DescriptorName: Antineoplastic Agents. DescriptorName: Disease-Free Survival. DescriptorName: Drug Eruptions. DescriptorName: Female. DescriptorName: Gastrectomy. DescriptorName: Gastrointestinal Stromal Tumors. DescriptorName: Humans. DescriptorName: Imatinib Mesylate. DescriptorName: Japan. DescriptorName: Male. DescriptorName: Middle Aged. DescriptorName: Neoadjuvant Therapy. DescriptorName: Neutropenia. DescriptorName: Organ Sparing Treatments. DescriptorName: Republic of Korea. DescriptorName: Stomach Neoplasms.
Neutropenia (2), Gastrointestinal Stromal Tumors (1), Stomach Neoplasms (1), more mentions
The American journal of tropical medicine and hygiene
CitationSubset: AIM. CitationSubset: IM. DescriptorName: Adrenal Cortex Hormones. DescriptorName: Drug Tolerance. DescriptorName: Erythema Nodosum. DescriptorName: Fatal Outcome. DescriptorName: Humans. DescriptorName: Immunosuppressive Agents. DescriptorName: Leprosy, Multibacillary. DescriptorName: Male. DescriptorName: Thalidomide. DescriptorName: Young Adult. Abstract: AbstractErythema nodosum leprosum (ENL), also known as type II leprosy reaction, is a severe immune-mediated complication of multibacillary leprosy.
Leprosy (2), Erythema Nodosum (2), Multibacillary Leprosy (1), more mentions
The Journal of dermatology
Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy..
Erythema (2), Drug Eruptions (2), more mentions
Contact dermatitis
Fixed drug eruption induced by ciprofloxacin and cross-reactivity to other quinolones..
Drug Eruptions (2), more mentions
Contact dermatitis
Two cases of eczematous drug eruption caused by oral tacrolimus administration..
Drug Eruptions (2), more mentions
Contact dermatitis
Non-pigmenting fixed drug eruption with mixed features of acute generalized exanthematous pustulosis induced by pseudoephedrine: a case report..
Acute Generalized Exanthematous Pustulosis (2), Drug Eruptions (2), more mentions
18. Drug eruption caused by memantine.  
Date: 07/02/2017
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Drug eruption caused by memantine..
Drug Eruptions (2), more mentions
The British journal of dermatology
We report the first case of a lichenoid eruption induced by a biosimilar to Infliximab after switching from infliximab... infusion of the biosimilar, the patient developed a pruritic papulosquamous eruption that was biopsied to reveal a lichenoid drug eruption. Possible mechanisms for lichenoid drug eruptions as a result of TNF-alpha inhibitor administration are discussed ...
Dermatology (1)
Drug Eruptions (3), Lichenoid Eruptions (1), more mentions
Melanoma research
He was treated successfully with topical corticosteroids without discontinuation of nivolumab. We report subcorneal pustular eruption as a novel cutaneous adverse event in patients on anti-PD1 therapy. Other neutrophilic eruptions (psoriasis, Sweet's syndrome, acute generalized pustulosis) have been reported in patients on anti-PD1 treatments, suggesting the neutrophil as another cell type modulated by anti-PD1 antibodies.
Dermatology (1)
Psoriasis (1), Sweet Syndrome (1), Drug Eruptions (1), more mentions
1 2  | Next Page»